Related Experiment Video

Updated: Aug 9, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Targeting GSK-3: a promising approach for cancer therapy?

Andrei V Ougolkov1, Daniel D Billadeau

  • 1Division of Oncology Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

Future Oncology (London, England)
|March 25, 2006
PubMed

Insights

Glycogen synthase kinase-3 (GSK-3) is a promising therapeutic target for neurological diseases and cancer. GSK-3 inhibition may treat tumors by regulating nuclear factor-kappaB (NF-kappaB) activity.

Area of Science:

  • Biochemistry
  • Oncology
  • Neuroscience

Background:

  • Glycogen synthase kinase-3 (GSK-3) is implicated in neurological disorders like Alzheimer's and bipolar disorder.
  • Its role in cancer is complex, with potential for both tumor promotion and suppression.
  • GSK-3beta is a key regulator of nuclear factor-kappaB (NF-kappaB) signaling.

Purpose of the Study:

  • To review the current understanding of GSK-3's role in human cancer.
  • To explore GSK-3 as a potential therapeutic target for various malignancies.
  • To discuss the molecular mechanisms underlying GSK-3's influence on tumor proliferation and survival.

Main Methods:

  • Literature review of recent studies on GSK-3 in cancer.
  • Analysis of GSK-3's interaction with key cancer-related pathways (e.g., beta-catenin, NF-kappaB).
  • Discussion of preclinical and clinical evidence regarding GSK-3 inhibitors in oncology.

Main Results:

  • GSK-3 plays a dual role in cancer, influencing cell proliferation and survival.
  • Inhibition of GSK-3beta can suppress tumor growth in cancers with active NF-kappaB.
  • Understanding GSK-3's mechanisms is crucial for targeted cancer therapies.

Conclusions:

  • GSK-3 is a significant therapeutic target for both neurological diseases and cancer.
  • Targeting GSK-3, particularly GSK-3beta, offers potential for treating various human malignancies.
  • Further research is needed to fully elucidate GSK-3's complex role in tumorigenesis and optimize therapeutic strategies.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...